Changes in eGFR for (A) all patients (n = 40), and those evaluated at (B) 3 months after discharge (n = 11), (C) 6 months after discharge (n = 2), (D) 9 months after discharge (n = 6), and (E) 12 months after discharge (n = 21).

<p>Changes in eGFR for (A) all patients (n = 40), and those evaluated at (B) 3 months after discharge (n = 11), (C) 6 months after discharge (n = 2), (D) 9 months after discharge (n = 6), and (E) 12 months after discharge (n = 21).</p

Multivariate analysis of risk factors associated with chronic kidney disease at follow-up among patients admitted for renal infarction.

<p>OR: odds ratio; CI: confidence interval.</p>a<p>Median served as the cutoff value.</p

Mean (±SD) eGFR and Cr of patients at admission and at 3 to 12 months after discharge (n = 40).

†<p>Paired t-test.</p

Baseline characteristics of study subjects admitted to the emergency department for renal infarction (n = 40).

<p>Baseline characteristics of study subjects admitted to the emergency department for renal infarction (n = 40).</p

Additional file 2: of Risk of incident active tuberculosis disease in patients treated with non-steroidal anti-inflammatory drugs: a population-based study

Calculation of attributable risk fraction and population attributable risk fraction of TB. (DOC 63 kb

Duration-response analysis.

<p>Duration-response analysis.</p

Subgroup analysis of the relationship between current use of fluoroquinolones and risk of composite gastric or intestinal perforation.

<p>Subgroup analysis of the relationship between current use of fluoroquinolones and risk of composite gastric or intestinal perforation.</p

Relationship between use of fluoroquinolones and risk of gastrointestinal perforation.

<p>Relationship between use of fluoroquinolones and risk of gastrointestinal perforation.</p

Sensitivity analysis using different outcome definition for current use of fluoroquinolone.

<p>Sensitivity analysis using different outcome definition for current use of fluoroquinolone.</p

Descriptive characteristics of patients with gastrointestinal perforation and controls.

<p>Descriptive characteristics of patients with gastrointestinal perforation and controls.</p